AQST — Aquestive Therapeutics Share News
0.000.00%
Last trade - 00:00- $590.87m
- $608.89m
- $44.55m
Aquestive Therapeutics Q1 revenue jumps on higher license and royalty income
Brief: Aquestive Therapeutics Announces Completion Of Type A Meeting With FDA For Anaphylm™ (Dibutepinephrine) Sublingual Film
Aquestive misses Q4 revenue estimates, EBITDA loss widens
Brief: Aquestive Therapeutics, Inc. Q4 Net Income USD -31.86 Million
Brief: Aquestive Therapeutics Appoints Internationally Recognized Allergist Dr. Matthew Greenhawt As Chief Medical Officer
Brief: Aquestive Therapeutics Announces FDA Issuance Of Complete Response Letter For Anaphylm
NASDAQ RESUMED AT 07:30 AM
US FDA declines to approve Aquestive's oral drug for allergic reactions (updated)
US FDA declines to approve Aquestive's oral drug for allergic reactions
NASDAQ TRADE HALT HALT NEWS PENDING AT 06:55 AM
U.S. STOCKS ON THE MOVE-Intel, Gartner, Chipotle
U.S. STOCKS ON THE MOVE-Spotify, Insmed, Nano Nuclear Energy
U.S. STOCKS ON THE MOVE-Broadcom, home lenders, First Solar
Aquestive Therapeutics falls as FDA flags issues with oral allergy drug
U.S. RESEARCH ROUNDUP- Blackline, Carmax, Expedia
Aquestive Therapeutics misses Q3 revenue, beats adjusted EBITDA estimates
Brief: Aquestive Therapeutics, Inc. Q3 Income From Operations USD -11.479 Million
Brief: Aquestive Therapeutics Announces Leadership Expansion To Support Growth
U.S. STOCKS ON THE MOVE- Shoe Carnival, Leidos Holdings, copper miners